Ana Balske

TL;DR: Estrogen-replacement therapy prevents osteoporosis in postmenopausal women by inhibiting bone resorption, but the balance between its long-term risks and benefits remains unclear.

TL;DR: Alendronate prevents bone loss in postmenopausal women under 60 years of age to nearly the same extent as estrogen-progestin and was well tolerated, with a safety profile similar to that of placebo or estrogen- Progestin.

TL;DR: In this article, four years of alendronate or estrogen-progestin therapy prevented postmenopausal bone loss and a residual effect was seen 2 years after alendralate therapy was stopped.

TL;DR: Bone mineral density response to once weekly delayed-release formulation of risedronate, given before or following breakfast, was non-inferior to that seen with traditional immediate-release risedonate given daily before breakfast.

TL;DR: In this article, a 2-year trial evaluated the efficacy and tolerability of a monthly oral regimen of risedronate for postmenopausal women with osteoporosis.